Dosing Begins in 3rd Phase 1 Study of AlzeCure’s ACD856
The first patient has been dosed in a Phase 1 study that will test multiple ascending doses of ACD856, AlzeCure Pharma‘s lead therapeutic candidate for Alzheimer’s disease. According to a company press release, the trial — the third Phase 1 study testing the oral ACD856 experimental therapy…